Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CoDa Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT01490879
First received: December 11, 2011
Last updated: April 29, 2014
Last verified: April 2014

December 11, 2011
April 29, 2014
July 2012
February 2014   (final data collection date for primary outcome measure)
Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment [ Time Frame: Within 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01490879 on ClinicalTrials.gov Archive Site
  • Percentage change in RDFU surface area [ Time Frame: Within 12 weeks ] [ Designated as safety issue: No ]
  • Time to RDFU complete closure [ Time Frame: Within 12 weeks ] [ Designated as safety issue: No ]
  • Percentage of granulation tissue in RDFU [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Incidence of ulcer recurrence [ Time Frame: 12 weeks post-closure ] [ Designated as safety issue: No ]
  • Incidence of adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)
A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon® in the Treatment of Subjects With a Diabetic Foot Ulcer

This study is for Type I or Type II diabetic subjects with with a diabetic foot ulcer. The study is being done to determine if Nexagon® plus standard of care is more effective than placebo plus standard of care. Standard of care will include debridement of the ulcer, standardized dressings and standardized off-loading using a Removable Cast Walker.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetic Foot Ulcers
  • Drug: Nexagon® Low Dose
    Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
  • Drug: Nexagon® Medium Dose
    Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
  • Drug: Nexagon® High Dose
    Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
  • Drug: Nexagon® vehicle
    Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
  • Experimental: Nexagon® Low Dose
    Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
    Intervention: Drug: Nexagon® Low Dose
  • Experimental: Nexagon® Medium Dose
    Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
    Intervention: Drug: Nexagon® Medium Dose
  • Experimental: Nexagon® High Dose
    Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
    Intervention: Drug: Nexagon® High Dose
  • Placebo Comparator: Nexagon® vehicle
    Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
    Intervention: Drug: Nexagon® vehicle
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
168
April 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosis of diabetes mellitus (Type I or II)
  2. HbA1c of less than or equal to 12.0%
  3. Diagnosis of neuropathic foot ulcer with partial or complete neuropathy
  4. Cutaneous ulcer on the plantar or dorsal aspect of the foot or toe that is greater or equal to 1.0cm2 and less than or equal to 8.0 cm2 in area at the end of the screening period and is full thickness with no exposed ligament, tendon, joint capsule or bone. Surface area will be measured by digital planimetry.
  5. The Medical Monitor(or delegate)must confirm that the reference diabetic foot ulcer (RDFU)is suitable for inclusion after reviewing digital photographs
  6. Wound bed consisting of completely viable tissue or one where completely viable tissue will be achieved by the end of the screening period.
  7. An Ankle Branchial Index (ABI) of greater or equal to 0.80 in concert with a bi- or tri-phasic Doppler flow pattern; or adequate circulation as demonstrated by any of the following methods: peri-wound transcutaneous partial pressure oxygen (TcpO2)greater or equal to 40 mmHg; or a toe pressure of greater or equal to 40 mmHg; or skin perfusion pressure of greater or equal to 40 mmHg.
  8. Ulcer present for 4 weeks or more or less than or equal to 12 months.
  9. Willing to wear a Removable Cast Walker (RCW) between study visits for the duration of the study.
  10. Signed informed consent form.

Exclusion Criteria:

  1. Any unstable medical condition that would cause the study to be detrimental to the subject.
  2. Decrease in RDFU size by more than 40% or increase in the ulcer size by more than 40% during the 14-day screening period as measured by digital planimetry.
  3. Ulcers caused primarily by untreated vascular insufficiency or ulcers with an etiology not related to diabetes.4. Ulcers above the ankle.

5. Ulcers that cannot be effectively off-loaded using the cast walker and sole insert provided in this study (ulcers not located on the weight bearing surface of the foot do not require off-loading).

6. Ulcers on the toes not accessible for photography (e.g. in the web space). 7. Presence of other ulcers within 2cm of the perimeter of the RDFU. 8. BMI > 45 9. Cannot tolerate or will not comply with the off-loading method, or non-compliance with standard or care.

10.The RDFU is infected (clinical assessment of infection)and/or biopsy proof of greater than 100,000 organisms per gram of tissue during the screening period.

11. Subjects presenting with the clinical characteristics of cellulitis at the ulcer site. 12. Necrosis, purulence, or sinus tracts that cannot be removed by debridement.13. Definite or suspected osteomyelitis within any wound located anywhere on the subjects body.14. Acute Charcot's neuroarthropathy as determined by clinical and/or previous radiographic examination.

15. Severe Charcot deformity or rocker bottom foot with an associated plantar mid-foot or heel ulcer.

16. Revascularization surgery on the leg with the wound to be treated less than or equal to 4 weeks prior to the start of the screening period.

17. Requirement for concurrent topical antimicrobials to treat the RDFU after the end of the screening period.

18. Received dermal substitute or living skin equivalent (e.g. Dermagraft® or Apligraf®) within 14 days prior of the start of the screening period.

19. Severe complications of diabetes that in the opinion of the Investigator could interfere with wound healing or impede the subject's participation.

20. Subjects on concurrent immunosuppressive therapy to include oral corticosteroid therapy equivalent to greater than 5 mg/day of prednisone.

21. Any history of radiation therapy to the foot. 22. Female subjects who are pregnant or lactating. 23. Pre-menopausal women not using effective birth control methods as determined by the Investigator. 24. Life expectancy of < 12 months. 25. Subjects on renal replacement therapy. 26. Cancer within the last 3 years except basal and squamous cell carcinoma. 27. Cancer within the RDFU

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Russian Federation,   Ukraine
 
NCT01490879
NEX-ULC-011
Yes
CoDa Therapeutics Inc.
CoDa Therapeutics Inc.
Not Provided
Principal Investigator: David G Armstrong, DPM MD PhD S.A.L.S.A. , University of Arizona, Tucson, AZ
CoDa Therapeutics Inc.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP